A new class of startups is scouting for deals - on both sides of the Pacific

It used to be that executing a global strategy meant finding a partner for the European market. Now, China has completely changed the way the world works. Startups have been in-licensing for years in a growing set of diseases. And now they are outlicensing to the US and Europe. What happens as more sophisticated R&D organizations go after novel drug targets? Lets find out.

First name

Last name

Company

Job Title

Country

Questions & Comments

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.